Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by Snowballgrowthon Jun 05, 2021 9:48am
99 Views
Post# 33335774

RE:RE:Exelon ...

RE:RE:Exelon ...
Chianchin wrote: On top of Biogen there are four more drug companes on phase 3 trial soon replace the 21 year old exelon. Monday the FDA will report on Biogen aproval. If the new drug is aproved say good by GUD'S  $160 M US dollar. The 5% wealthy in Latam go to Miami to get the best drugs. The same fact applied for covid-19 vaccine while the rest of the Latam population are geting the cheaper or free vaccine from Chine and Russia. Sanofi new of the upcoming new drugs and was very astute in selling Excelon before the Biogen and the other four companies FDA results.   


So you think Exelon's value is zero if Biogen gets that approval ?

<< Previous
Bullboard Posts
Next >>